-
Mon news: Pfizer leads industry earnings for Q3. Ascend gets $135M funding for ADC pipeline. Positive TAVI trial for Edwards. Halozyme quits Evotec pursuit. AZ prostate cancer trial success. See more on our front page
Karyopharm - oncology
- Thread starter anonymous
- Start date
-
- Tags
- None
Wow, as much you feel he’s worthless, he must be a genius then to be able to fool, the BOD, institutional investors, and the SEC.
If the BOD thought he was the problem they could remove him quickly, just like they did with MK. If the institutions thought he was the problem they could proxy out the entire BOD, RP included.
If the SEC thought he was intentionally or unintentionally running the company into the ground for his own benefit they could investigate and prosecute.
You seem to be venting from a personal and dramatic perspective on him…it’s odd.
The company was headed in this direction well before the stock fell. That’s on MK and led to his dismissal. Like most, if not all, small cap biotech’s the data will drive the markets they can play in and what revenue potential there is. It’s not that complex. There is no lever any CEO could pull to get Seli to drive more revenue in the two small indications…they need the Endo and MF data to read out positively…if one or both do KPTI will go up. If they both go bad, it’s over…regardless of the CEO.
The board has no balls. It’s going to take an activist investor to get this done.
Ok, then why have none of our institutional investors initiated a proxy ballot to remove board members and add their own?
Try removing the emotion from this. Our largest institutional investors know the timeline. No CEO can change the readout timing based on events, despite what some people on here are saying. The CRO’s and IRB’s control the data and its timing.
For the 1000th time, the two readouts will dictate the success or failure of KPTI. Until then there is no catalyst for the share price to move dramatically.
Leadership has totally mismanaged "runway". Why was Europe delayed in starting S2. CEO was supposed to be an "expert" in that region. Why werent costs cut earlier to extend runway ?? Why was money spent to take a photo with "mcdreamy". Why was there a delay in enrolling S2 in US and why was MF late to the game to enroll ?? Why as MM phase 3 pushed out again ?? Why were leadership given pay increases when they failed to hit important milestones?? Yes, you are correct, data is everything; yet leadership keeps fumbling the ball so much we may never even get to data and if we do our stock options will be nearly worthless from so much dilution. You are making my case for me dolt. You must be MM for sure
) lolnow, the mods are blocking negative posts on leadership. The leadership team must be cryin to them instead of working for shareholders and employees. Go DO YOUR JOB
The 'balls to get this done' lie in getting the trials enrolled ASAP and getting to the readouts. It also lies in seriously exploring either a filing on Siendo EC or an AA on the current data as the FDA could have a peak at the Xport EC data. They have the safety history. I have heard the arguments that the trial wasn't designed in line with Subpart H and that it is sub-group analysis, however the FDA does have wiggle room in the process if they choose. Initial feedback on Siendo EC readout was that the data was 'not likely' sufficient to support a filing, but the company fought an even higher threshold to get approved in MM. I would suspect the FDA would push through ODAC review and given how the Geron panel went they would likely come to a similar recommendation which the FDA would have difficulty denying. Considering we also have the confirmatory trial hitting on a lower dose it very positive. Most don't think management has the guts to do this and I would also say that they also don't have the guts to run this through readouts as there is risk that the data does not come out as strong. They might have to run through the trial readouts, but I think they are looking for an exit sooner than later because of the readout risk. I suspect they have been shopping the company since ASCO last year and that establishing a focused strategy was an 'in case we don't get a buyer' strategy. If they were going to run through readouts there would have been better execution and hiring of key regulatory staff earlier. Thier 6 month Royalty Pharma debt deal was to give them room to stay out of a going concern period while they marketed the data. Since a buyer hasn't emerged they were forced to take this crappy debt deal that simply delayed the going concern period by another 7-8 months. This deal also accomplished one thing and that is to facilitate the right price they are looking for as I suspect they want $2B upfront and possible CVR. Previously this would have required a share price of $16.50, which no company could justify that type of multiple. With the share float almost doubled they are more likely to get to the dollar figure they want as they care about the full deal price not the share price. Merck and Incyte are likely suitors as they have to replace key products in EC and MF in the next few years. The Morphosys acquisition is a major threat to Rux in the medium term and they havn't been able to come up with better options. Merck is not finding additional success in new Keytruda trials and candidates to replace that loss of $25B per year that is coming. While Karyopharm isn't in the strongest position, there are strong players out there that will become weaker soon if they can't find success. Incyte's position on acquisitions has changed notably from JPM to their latest earnings call as Rux is getting cannibalized now.
Leadership has totally mismanaged "runway". Why was Europe delayed in starting S2. CEO was supposed to be an "expert" in that region. Why werent costs cut earlier to extend runway ?? Why was money spent to take a photo with "mcdreamy". Why was there a delay in enrolling S2 in US and why was MF late to the game to enroll ?? Why as MM phase 3 pushed out again ?? Why were leadership given pay increases when they failed to hit important milestones?? Yes, you are correct, data is everything; yet leadership keeps fumbling the ball so much we may never even get to data and if we do our stock options will be nearly worthless from so much dilution. You are making my case for me dolt. You must be MM for sure
Are you high? How do any of your above ramblings equate to anything relevant? If you truly need an explanation to any of your questions you are the dolt.
The CEO strikes me as a lad without much fortitude or backbone so I would see him take the easy way out rather than roll the dice. To sell the company for a lower share price than when he was hired even after compelling data points is a complete failure. A share price of $9 is what a 2b deal would look like. Cvr would have to be no less than 4. I only see a buyer entering picture at least after phase 2 single agent mf releases some data. That will give buyers a sense of single agent activitiy.
Little dickey likes gaslight manifestos after he destroys value...he is of course a genius in his own mind
This has been going on for a while. They’re incredibly paranoid and insecure.
Buffet would steer clear of this place.
Warren Buffett Points Out 1 Sign to Quickly Spot Someone With Bad Leadership Skills | Inc.com
https://www.inc.com/marcel-schwantes/warren-buffett-points-out-1-clear-sign-of-a-bad-leader.html
“We look for intelligence, we look for initiative or energy, and we look for integrity. And if they don't have the latter, the first two will kill you, because if you're going to get someone without integrity, you want them lazy and dumb.”
Warren Buffett Points Out 1 Sign to Quickly Spot Someone With Bad Leadership Skills | Inc.com
https://www.inc.com/marcel-schwantes/warren-buffett-points-out-1-clear-sign-of-a-bad-leader.html
“We look for intelligence, we look for initiative or energy, and we look for integrity. And if they don't have the latter, the first two will kill you, because if you're going to get someone without integrity, you want them lazy and dumb.”
We can all speculate and try to read the tea leaves, but the most transparent and telling thing about this dumpster fire called "company" is not one single member of the leadership has stepped up to buy stock in the open market. They can try to hype everything, "absolutely....absolutely" but what about showing us your conviction for the future of this place......let see you put it where your mouths are. Look at little Allogene. They are in similar spot, stock fell hard......read outs late 2026. What did the c suite do there.....they bought the shit out of the stock across the board and oh, btw, it's up ten percent as a result. We are headed for extinction and I'm afraid it's bc of lack of action from every angle. Can't have a JV squad compete against Olympians bottom line.
I guess I hit another nerve from our leadership team not buying any stock on open market. It seems that they took that post down. Censorship in our hallways is as f'ed up as this company. Why dont you buy some stock if you think our company is going to be successful? Why not put your money where your mouth is ??? Why not??????